SG Americas Securities LLC Decreases Stock Position in NGM Biopharmaceuticals, Inc. (NASDAQ:NGM)

SG Americas Securities LLC lessened its position in NGM Biopharmaceuticals, Inc. (NASDAQ:NGMGet Rating) by 23.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 58,160 shares of the company’s stock after selling 17,510 shares during the quarter. SG Americas Securities LLC owned about 0.07% of NGM Biopharmaceuticals worth $887,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Acadian Asset Management LLC acquired a new stake in shares of NGM Biopharmaceuticals in the fourth quarter valued at approximately $30,000. Exane Derivatives increased its holdings in shares of NGM Biopharmaceuticals by 2,163.4% in the fourth quarter. Exane Derivatives now owns 2,105 shares of the company’s stock valued at $37,000 after purchasing an additional 2,012 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of NGM Biopharmaceuticals by 139.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,921 shares of the company’s stock valued at $109,000 after purchasing an additional 4,032 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of NGM Biopharmaceuticals in the fourth quarter valued at approximately $151,000. Finally, Dupont Capital Management Corp acquired a new stake in shares of NGM Biopharmaceuticals in the fourth quarter valued at approximately $171,000. Hedge funds and other institutional investors own 58.50% of the company’s stock.

Analyst Upgrades and Downgrades

NGM has been the subject of several recent research reports. Jefferies Financial Group initiated coverage on NGM Biopharmaceuticals in a report on Wednesday, July 20th. They issued a “buy” rating and a $25.00 price target for the company. The Goldman Sachs Group cut their price target on NGM Biopharmaceuticals from $34.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, May 24th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.86.

Insider Transactions at NGM Biopharmaceuticals

In other news, Director Group L. P. Column purchased 984,161 shares of the stock in a transaction dated Thursday, June 9th. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $13,286,173.50. Following the completion of the transaction, the director now directly owns 2,650,177 shares in the company, valued at approximately $35,777,389.50. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Group L. P. Column bought 83,175 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The stock was purchased at an average cost of $10.79 per share, for a total transaction of $897,458.25. Following the completion of the acquisition, the director now owns 902,090 shares in the company, valued at approximately $9,733,551.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Group L. P. Column bought 984,161 shares of the firm’s stock in a transaction that occurred on Thursday, June 9th. The stock was bought at an average price of $13.50 per share, with a total value of $13,286,173.50. Following the completion of the acquisition, the director now owns 2,650,177 shares of the company’s stock, valued at approximately $35,777,389.50. The disclosure for this purchase can be found here. Insiders bought a total of 1,394,261 shares of company stock worth $18,377,237 over the last ninety days. Company insiders own 38.10% of the company’s stock.

NGM Biopharmaceuticals Stock Down 3.3 %

NGM stock opened at $14.48 on Monday. The business has a fifty day moving average of $14.16 and a two-hundred day moving average of $14.63. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -8.94 and a beta of 1.71. NGM Biopharmaceuticals, Inc. has a 52-week low of $10.49 and a 52-week high of $27.25.

NGM Biopharmaceuticals (NASDAQ:NGMGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.42) EPS for the quarter, hitting the consensus estimate of ($0.42). NGM Biopharmaceuticals had a negative return on equity of 36.46% and a negative net margin of 162.11%. The business had revenue of $20.95 million during the quarter, compared to analyst estimates of $22.35 million. As a group, sell-side analysts anticipate that NGM Biopharmaceuticals, Inc. will post -2.1 EPS for the current year.

NGM Biopharmaceuticals Profile

(Get Rating)

NGM Biopharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH.

Featured Articles

Institutional Ownership by Quarter for NGM Biopharmaceuticals (NASDAQ:NGM)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.